SCHEMBL6802464

SCHEMBL6802464

N#CC(C(N)=O)c1ccc(Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
MAPT P10636 2/20 0.41
HTT P42858 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
NSD2 O96028 1/20 0.41
KMT2A Q03164 3/20 0.40
BRD4 O60885 1/20 0.40
GABBR2 O75899 3/20 0.40
GABBR1 Q9UBS5 3/20 0.40
CYP2C9 P11712 3/20 0.40
LMNA P02545 2/20 0.40
TSHR P16473 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C19 P33261 2/20 0.40
MEN1 O00255 2/20 0.40
CYP3A4 P08684 1/20 0.40
ADORA3 P0DMS8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11810764 0.84 HDAC4 (0.47) HDAC4HDAC7HDAC5MAPTHTT
SCHEMBL2542929 0.84 HDAC4 (0.47) HDAC4HDAC7HDAC5MAPTHTT
SCHEMBL6795829 0.82 ESR1 (0.52) SMN1; SMN2KMT2ACYP2C9TSHRCYP2C19
SCHEMBL2928841 0.81 PARP15 (0.43) MAPTHTTNSD2GAA
SCHEMBL21383218 0.81 LMNA (0.51) HDAC4HDAC7HDAC5HTTSMN1; SMN2
SCHEMBL2926595 0.81 PARP15 (0.43) MAPTHTTNSD2GAA
SCHEMBL7740756 0.81 BRD4 (0.53) HDAC4HDAC7HDAC5MAPTHTT
SCHEMBL18172114 0.81 MEN1 (0.47) SMN1; SMN2NPSR1KMT2ALMNACYP2C19
SCHEMBL6802932 0.80 SLC6A3 (0.44) HTTSMN1; SMN2LMNATSHRALDH1A1
SCHEMBL2927032 0.80 TSHR (0.48) HDAC4HDAC7HDAC5HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3286178-A1 AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS Almirall S.A. (ES) 2018-02-28 EP disclosed
WO-2016170009-A1 AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS ALMIRALL, S.A. (ES) 2016-10-27 WO disclosed
US-6730671-B2 ENZYME INHIBITOR TREATING AUTOIMMUNE DISEASES, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2004-05-04 US disclosed
US-20030158406-A1 Compounds useful as reversible inhibitors of cathepsin S BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-08-21 US disclosed
US-6608057-B2 Compounds useful as reversible inhibitors of cathepsin S BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-08-19 US disclosed
US-20020091259-A1 Compounds useful as reversible inhibitors of cathepsin S CYWIN CHARLES L (US) 2002-07-11 US disclosed
US-6395897-B1 DRUGS FOR ENZYME INHIBITORS ANTICOAGULANTS AND TREATMENT OF AUTOIMMUNE DISEASE BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2002-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091259-A1 Compounds useful as reversible inhibitors of cathepsin S CTSS, CTSB, CTSV HDAC4 521/4885HDAC7 204/4885HDAC5 408/4885
US-20030158406-A1 Compounds useful as reversible inhibitors of cathepsin S CTSS, CTSB, CTSV HDAC4 521/4885HDAC7 204/4885HDAC5 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.